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The genomes of commonly used variants of human cytomegalovirus (HCMV) strains Towne and
AD169 each contain a substantial mutation in which a region (UL/b9) at the right end of the long
unique region has been replaced by an inverted duplication of a region from the left end of the
genome. Using high-throughput technology, we have sequenced HCMV strain Towne (ATCC VR-
977) and confirmed the presence of two variants, one exhibiting the replacement in UL/b9 and the
other intact in this region. Both variants are mutated in genes RL13, UL1, UL40, UL130, US1 and
US9. We have also sequenced a novel AD169 variant (varUC) that is intact in UL/b9 except for a
small deletion that affects genes UL144, UL142, UL141 and UL140. Like other AD169 variants,
varUC is mutated in genes RL5A, RL13, UL36 and UL131A. A subpopulation of varUC contains
an additional deletion affecting genes IRS1, US1 and US2.
Human cytomegalovirus (HCMV; species Human herpes-
virus 5) was first isolated over 50 years ago (Craig et al.,
1957; Rowe et al., 1956; Smith, 1956). The most widely
used laboratory strains are Towne (Plotkin et al., 1975) and
AD169 (Rowe et al., 1956). Both have been distributed
widely and developed as vaccine candidates, and over the
years their detailed histories have become obscure.
Moreover, the fact that the biological properties of these
strains are not conserved between stocks (Brown et al.,
1995) demonstrates the existence of genetic variants, and
this may affect the interpretation of experimental studies.
This paper contributes to the characterization of variants
present in the ATCC VR-977 stock of Towne and of
commonly used variants of AD169 in comparison with a
novel, genetically more intact variant.
As shown in Fig. 1, the commonly used variants of Towne
and AD169 arose from wild-type HCMV genomes
(236 kb) via replacement of a region (UL/b9) at the right
end of UL (Cha et al., 1996; Davison et al., 2003b; Dolan
et al., 2004; Dunn et al., 2003; Murphy et al., 2003;
Prichard et al., 2001). These large-scale lesions were
accompanied by additional mutations. AD169 has frame-
shifts in genes RL5A, RL13 and UL131A (Akter et al., 2003;
Davison et al., 2003a, b; Yu et al., 2002) and a substitution
in gene UL36 that inactivates the encoded inhibitor of
apoptosis (Skaletskaya et al., 2001). Towne has frameshifts
in genes RL13 and UL130 (Dolan et al., 2004).
The Towne genome sequence has been determined (Dunn et
al., 2003; Murphy et al., 2003) from a bacterial artificial
chromosome (BAC) constructed from plaque-purified
ATCC VR-977 (Marchini et al., 2001). However, ATCC
VR-977 is known to contain a mixture of two variants
(Hahn et al., 2003). One (Towne varRIT3 or Towneshort;
here called varS) is represented in the BAC and, as described
above, lacks UL/b9. The other (Townelong; here called varL) is
intact in UL/b9, and this region has been sequenced (Dolan et
al., 2004).
3Present address: BioReliance Ltd, Todd Campus, West of Scotland
Science Park, Glasgow G20 0XA, UK.
The GenBank/EMBL/DDBJ accession numbers for the genome
sequences of HCMV strains Towne and AD169varUC are FJ616285
and FJ527563, respectively.
The Illumina Genome Analyzer sequence datasets are available from the
corresponding author.
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We determined the sequence of ATCC VR-977 by aligning
data obtained from an Illumina Genome Analyzer (http://
www.illumina.com) against a constructed reference
sequence. To obtain the reference, the more reliable of
the two varS BAC sequences (AC146851; Murphy et al.,
2003) was reorganized into a genome-equivalent arrange-
ment after identifying the termini and removing insertions
in gene UL32 and the origin of DNA replication. The varS
reference was generated from this sequence by inserting the
region containing genes IRS1–US12 from strain Merlin
(AY446894; Dolan et al., 2004) in place of the plasmid
vector, which had replaced these genes during generation
of the BAC. The varL reference was then constructed by
inserting the UL/b9 sequence (GenBank accession no.
AY446869; Dolan et al., 2004) into the varS reference in
place of the duplication that had originally replaced UL/b9.
The Illumina data were derived from whole cell DNA
extracted from human fetal fibroblasts infected with ATCC
VR-977, and assembled and viewed using Maq and
Maqview (Li et al., 2008; http://maq.sourceforge.net). A
total of 47.1 % of the 5 079 235 sequences (50 nt each)
aligned with the derived varL consensus and the coverage
was 516 reads per nt. Test assemblies using appropriate
references confirmed that ATCC VR-977 contains both
varL and varS, and showed that the whole population has
frameshifts in genes RL13, UL1, UL130, US1 and US9. In
addition, a 346 bp deletion in gene UL40 was present in
almost the whole population, though detection of very
sparse data from the deleted region indicated that a small
proportion (much less than 1 %) of genomes might be
intact. This deletion implies that varL and varS do not
encode the gene UL40 signal peptide sequence, which
contributes to natural killer (NK) cell evasion by
upregulating human lymphocyte antigen-E (Tomasec
et al., 2000). Eighteen clear single nucleotide polymorph-
isms (SNPs) were identified, but these could not be
assigned to particular variants. In addition to the presence
of UL/b9, and excluding the duplicate copies of the inverted
repeats, ATCC VR-977 differed from the varS BAC at 40
loci consisting of 34 substitutions and six insertions. By
referring to sequences available for other HCMV strains, it
was possible to infer which sequence was mutated at 25
loci. The BAC was assessed as being mutated at 23 and
ATCC VR-977 at one, with the remaining substitution
corresponding to an SNP.
In contrast with ATCC VR-977, in which varL has retained
UL/b9, all commonly used AD169 stocks lack this region.
Therefore, it was of interest that one of us possessed an
AD169 stock (varUC) that reputedly contained UL/b9
sequences. N. Lurain had received varUC at the University
of Chicago from K. Thompson, who in turn had obtained
it from M. Beem in 1981 at the same institution. No
documentation was available on its history, but it was
thought to have undergone at least 50 passages since its
acquisition. Initial studies (N. Lurain, unpublished data)
had demonstrated that varUC plaques were similar to those
of strain Toledo (Kemble et al., 1996), which contains
UL/b9 (Cha et al., 1996), appearing as clusters of refractile,
rounded cells, rather than the well-separated, elongated
cells characteristic of commonly used AD169 variants.
Also, sequencing had revealed the presence of UL/b9 genes
in varUC, specifically UL146 and a region containing the 39
end of UL144 and the 59 end of UL140 with a 3.2 kb
deletion encompassing the intervening genes UL142 and
UL141. Moreover, genotyping data from microarray
experiments had indicated the presence of all UL/b9 genes
except UL142 and UL141 (J. Garcı´a-Ramı´rez, D. Foster, L.
Buehler, N. Lurain & P. Ghazal, unpublished data). These
findings implied that varUC is either an AD169 variant that
has retained most of UL/b9 or another strain entirely.
In order to distinguish between these possibilities, several
genes that are mutated in commonly used AD169 variants
or that vary greatly between HCMV strains were amplified
by PCR from DNA extracted from a stock of cell-released
varUC and sequenced; UL/b9 was also sequenced in its
entirety. These data were compared with the published
genome sequences of two AD169 variants. One of these was
Fig. 1. Schema for the derivation of the major lesion in the genome of commonly used AD169 variants from a wild-type virus
genome; lengths are shown to scale. In the wild-type genome, the long and short unique sequences (UL and US; shown as
thinner structures) are flanked by inverted repeats (ba/b9a9 and ca/c9a9; shown as thicker structures). As indicated by the dashed
lines, the AD169 genome was generated by replacing a region at the right end of UL (UL/b9; shaded grey) by an inverted duplication
of a region from the left end of the genome (arrow). This resulted in UL becoming shorter by 15 kb (19 genes) and b/b9 becoming
longer by 10 kb (six genes and part of another). A similar phenomen occurred in the derivation of the Towne varS genome, with UL
becoming shorter by 13 kb (15 genes) and b/b9 becoming longer by 11 kb (seven genes and part of another).
A. J. Bradley and others
2376 Journal of General Virology 90
varUK, for which the sequence (X17403) was derived by
Chee et al. (1990) and updated (BK000394) by the
correction of errors and the insertion of a 929 bp region
that is absent from certain stocks (Dargan et al., 1997;
Mocarski et al., 1997). The other was varATCC, for which
the sequence (AC146999) was derived by Murphy et al.
(2003) from a BAC generated from plaque-purified ATCC
VR-538 (Yu et al., 2002). In the 16976 bp of the 28780 bp
determined for varUC that were comparable with varUK
and varATCC, all three genomes were closely similar. The
presence of UL/b9 in varUC, except for the previously
characterized 3.2 kb deletion, was confirmed. This deletion
is predicted to result in lack of expression of the UL144,
UL142 and UL141 proteins, and expression of the UL140
protein with the C-terminal eight residues replaced by 71
residues specified by a reading frame that overlaps UL144.
The partial information obtained was consistent with
varUC being an AD169 variant, and formed the basis for
deriving the complete genome sequence from Illumina data
derived from DNA extracted from pelleted cell-free virions. A
reference was constructed from the varUK sequence, utilizing
the partial varUC data to amend differences, and inserting
UL/b9 in place of the duplication that had originally replaced
UL/b9. A total of 92.4 % of 6 264 332 sequences (50 nt each)
aligned with the derived varUC consensus, and the coverage
was 1267 reads per nt. Test assemblies and PCR experiments
demonstrated the absence of the UL/b9 deleted form
characteristic of varUK and varATCC and the 929 bp deleted
form present in some varUK stocks. The 3.2 kb deletion in
UL/b9 was confirmed as being a feature of the entire
population, and a 3.7 kb deletion in c9/US, which affects
genes IRS1, US1 and US2, was detected in the majority of the
population. Test assemblies also showed that the entire
varUC genome population contained the mutations in
RL5A, RL13, UL36 and UL131A present in varUK and
varATCC. Four clear SNPs were identified.
Table 1. Nucleotide substitutions in AD169 variants
ND, Substitutions where the mutant and non-mutant residues could
not be distinguished; CR, synonymous substitutions or substitutions
not located in protein-coding regions; SUB, non-coding and
synonymous substitutions.
Nucleotide* Mutated variant Region affected EffectD
971 varUC CR SUB
1059 varATCC RL1 LAS
1080 varATCC RL1 TAR
1095 varATCC RL1 QAR
1166 varATCC RL1 CAS
1270 ND RL1 Q$H
1403 varATCC RL1 CAR
1672 varATCC RL1 IAM
1749 varATCC RL1 SAzd
1925 varATCC RL1 WAR
2337 varATCC CR SUB
2781 varATCC CR SUB
2898 varATCC CR SUB
3337 varATCC CR SUB
5080 varUC RL5A§ SUB
8318 varATCC/varUK RL10 NAD
27980 varATCC UL23 SUB
29374 varATCC UL24 FAL
42128 varATCC UL32 EAG
56856 varUC UL44 AAS
98223 varATCC CR SUB
103266 varUC UL70 HAY
108681 varUC UL74A SUB
114378 varATCC UL78 SAF
118556 varUC UL82 DAA
118730 varATCC/varUK UL82 RAP
134412 varATCC/varUK UL89 AAS
136946 varATCC UL93 AAD
145916 varATCC UL99 FAS
155061 varATCC UL105 SUB
160678 varATCC UL111A KAR
175085 varUC CR SUB
191003 ND b9 SUB
191021 ND b9 SUB
191043 ND b9 SUB
191071 ND b9 SUB
191113 ND b9 SUB
191146 ND b9 SUB
191277 ND b9 SUB
191334 ND b9 SUB
191336 ND b9 SUB
191588 ND a9 SUB
191635 ND a9 SUB
191743 varATCC a9 SUB
192163 varATCC c9 SUB
192244 varUC/varUK c9 (TRS1/IRS1) SUB
192325 varATCC/varUC c9 (TRS1/IRS1) SUB
192434 varATCC c9 (TRS1/IRS1) SAG
192723 varATCC c9 (TRS1/IRS1) LAP
192770 varUC c9 (TRS1/IRS1) VAL
192983 varUC c9 (TRS1/IRS1) TAP
197200 varATCC CR SUB
Table 1. cont.
Nucleotide* Mutated variant Region affected EffectD




*Location in the varUC genome sequence (FJ527563; 231781 bp).
This excludes the duplicate copies of the inverted repeats (i.e. ab and
ca) and 12 substitutions (nt 222147–223855) in a region of the
varATCC sequence that was replaced during construction of the BAC.
This replacement appears to have originated from a strain other than
AD169 (probably Toledo).
DFor non-synonymous substitutions, an arrow indicates the change
from the non-mutant to the mutant amino acid residue. Where it was
not possible to distinguish the non-mutant and mutant residues, the
alternatives are separated by a filled circle.
dTermination codon indicated by z.
§Frameshifted in all variants and therefore considered non-coding.
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Given the apparent existence of a vast number of
differentiable HCMV strains (e.g. Bradley et al., 2008;
Rasmussen et al., 2003), the high degree of sequence
similarity between the three variants and the sharing of
several mutations in common, confirmed that varUC is an
AD169 variant. Differences due to insertions included the
presence of UL/b9 in varUC, length variations in the
tandem repeat in a/a9 and heterogeneity in several non-
Fig. 2. Schema for the derivation of AD169 variants from the original clinical material, based on the assumption that varATCC
was generated from a US source and not from importation of varUK. Mutations in RL5A, RL13, UL36 and UL131A (and perhaps
other, undetected mutations resulting in amino acid substitutions or affecting non-coding sequences) arose during the 14
passages that led to NIH 76559 and were inherited by all three lineages. Later on during the 14 passages, the deletion of UL/b9
occurred, and this was inherited by varUK and varATCC from NIH 76559. The 3.2 kb deletion in UL/b9 that characterizes varUC
occurred either at an intermediate stage as a precursor of the larger deletion or in the separated lineage. Genes that are
detectably disabled, and other mutations whose effects are unknown (Table 1), are listed below each variant.
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coding polynucleotide tracts. Substitutions were identified
at 54 loci (Table 1), with over half (29) in bac/b9a9c9 and the
adjacent sequence at the left end of UL, and 32 in protein-
coding regions (five synonymous and 27 non-synonym-
ous). By referring to sequences available for other HCMV
strains, it was possible to infer which sequence was mutated
at 42 loci. A total of 36 mutations were specific to a single
variant: nine to varUC and 27 to varATCC. Each of the
remaining six mutations was present in pairs of variants:
one in varUC/varUK, two in varATCC/varUC and three in
varATCC/varUK.
Given the lack of historical information, it is not possible
to reconstruct fully the lineages that led to the three AD169
variants. AD169 was isolated at the National Institutes of
Health (Bethesda, MD, USA) from the adenoids of a 7-
year-old girl and passaged 14 times in human fibroblast
cells to yield a stock named NIH 76559 (Rowe et al., 1956).
The lineage that led to varUK was initiated by researchers
at St George’s Hospital Medical School (London, UK), who
obtained NIH 76559 in 1960 and passaged it 40 times in
human fibroblast cells. The resulting virus was used to
make batches of a potential vaccine by 16–24 additional
passages (Elek & Stern, 1974). The varUK sequence was
determined from a set of plasmid clones generated from a
plaque-purified derivative of one of these passages (Oram
et al., 1982). The route by which varATCC was derived
from NIH 76559 is less clear, but it seems likely that it
originated from an exclusively US lineage, since a US
researcher, W. A. Chappell, deposited the stock with the
ATCC. The ATCC has declined to reveal to us when this
occurred, but has distributed AD169 at least since 1973
(e.g. Smith & de Harven, 1973), and now markets it as
ATCC VR-538. The relatively large number of mutations
specific to varATCC is consistent with the impressive
numbers of passages to which AD169 was subjected in early
years in some US laboratories (e.g. 232 passages by Vonka
& Benyesh-Melnick, 1966). If varATCC indeed originated
from a purely US source, a schema of the type illustrated in
Fig. 2 may be proposed. However, resolution of the details
is confounded by the potential persistence of mutations
(including those that may have arisen in the ancestor of
any two or all three variants) to different extents in
subsequent lineages, and to the fact that the varUK and
varATCC sequences originated from molecular clones
made from plaque-purified viruses and therefore do not
necessarily represent whole populations.
Like many other passaged HCMV strains, the Towne and
AD169 variants are mutated in gene RL13 and one of the
three genes in the UL128 locus (UL128, UL130 and
UL131A) (Akter et al., 2003; Dolan et al., 2004; Hahn et al.,
2004). This implies strong selection during passage in
human fibroblasts against the encoded functions, which are
involved in cell tropism (reviewed by Sinzger et al., 2008a).
Towne varS and the AD169 variants are also mutated in
UL/b9, as is strain TB40/E, which is frameshifted in UL141,
with a derivative additionally lacking UL145 and UL144
(Dolan et al., 2004; Sinzger et al., 2008b; Tomasec et al.,
2005). The patterns of mutation suggest that more than
one gene in this region (UL145, UL144, UL142, UL141 or
UL140) may be selected against, though not as strongly as
RL13 and the UL128 locus. It is not immediately apparent
why expression of these genes might be deleterious. The
proteins encoded by UL142 and UL141 are involved in
evasion of NK cell function, the former by downregulating
MICA, which is a ligand for the activating receptor NKG2D
(Chalupny et al., 2006; Wills et al., 2005), and the latter by
sequestering CD155 (PVR), which is a ligand for the
activating receptors CD226 (DNAM-1) and CD96
(TACTILE) (Tomasec et al., 2005). The UL144 protein
activates NF-kB in a TRAF6-dependent manner, causing
upregulation of the chemokine CCL22 (MDC) (Poole et
al., 2008), and also inhibits T cell proliferation by binding
CD272 (BTLA) (Cheung et al., 2005).
We have contributed towards the characterization of
variants of HCMV strains Towne and AD169, so that
biological data may be assessed with greater rigour. The
sequence of Towne ATCC VR-977 confirmed the presence
of two major variants (varL and varS) and extended
knowledge of their shared mutations. A novel AD169
variant (varUC) was shown to be genetically more intact
than varUK and varATCC and may be a new tool in the
hands of HCMV researchers.
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